GlassScriptPhysician profile
James J Koster
NPI 1851387344
$1,401.41
in general payments reported to CMS, 2019-2025
19 companies · $350 in 2025
The $350 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $28.71 · 2021: $100 · 2022: $245 · 2023: $109 · 2024: $462 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $921.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $161.88 | 2022-2025 | |
| Lensar, INC. | $160.75 | 2022 | |
| Lumenis Be INC | $135.97 | 2024 | Optilight |
| Glaukos Corporation | $122.14 | 2021-2025 | Idosetr |
| Tarsus Pharmaceuticals, INC. | $118.14 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $117.10 | 2022-2024 | Tecnis Iol, Tecnis Iol |
| Allergan, INC. | $106.65 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $99.28 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $95.16 | 2023-2025 | Rocklatan, Tryptyr |
| Thea Pharma INC. | $55.48 | 2024-2025 | Iyuzeh |
| Amgen INC. | $50.30 | 2025 | Tepezza |
| Harrow Eye, LLC | $50.14 | 2024-2025 | Vevye |
| Astellas Pharma US INC | $22.76 | 2024 | Izervay |
| Ocular Therapeutix, INC. | $22.47 | 2025 | Dextenza |
| Sun Pharmaceutical Industries INC. | $21.14 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $19.04 | 2024 | |
| Dompe US, INC. | $16.03 | 2025 | Oxervate |
| Sight Sciences, INC. | $15.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Koster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.